The question millions of GLP-1 patients have been asking -- what happens when I stop? -- now has a clinical answer, and it is not reassuring. A study published in BMJ Medicine on March 18 found that patients who discontinued GLP-1 receptor agonists for two years faced a 22 percent increased risk of major adverse cardiovascular events, including heart attack, stroke, and cardiovascular death, compared with those who continued treatment [1].

As we covered in our previous reporting, the study analyzed data from Truveta, using real-world clinical records to emulate a target trial comparing continued GLP-1 use against discontinuation. The findings were consistent across subgroups and held even after adjusting for weight regain [2].

The cardiovascular benefits of GLP-1 drugs have been established by multiple large trials over the past three years. Patients who stay on the medication for three or more years see an 18 percent reduction in cardiovascular risk, according to CNBC's reporting on the study [3]. But the new research shows those benefits begin eroding within six months of stopping, with the risk gap widening steadily over two years.

Washington University's research summary put the finding starkly: "The longer the gap in treatment, the bigger the jump in risk" [4]. CNN reported that the study aligns with a separate BMJ meta-analysis published in January showing that cessation of weight management medications is followed by rapid weight regain and reversal of cardiometabolic improvements [5].

For patients, the implications are profound. If GLP-1 drugs must be taken indefinitely to maintain cardiovascular benefits, the lifetime cost at current pricing -- roughly $1,000 per month for brand-name injectables -- becomes a central health equity question. Patients who cannot afford to continue, or whose insurance coverage lapses, face not merely weight regain but elevated heart risk [6].

The Educated Patient, a health literacy publication, emphasized that the 22 percent figure represents relative risk, not absolute risk, meaning the real-world impact varies by individual baseline risk. But for patients with Type 2 diabetes and existing cardiovascular disease -- the population most commonly prescribed GLP-1 drugs -- even a relative increase of that magnitude is clinically significant.

Healio reported that some cardiologists are now recommending that patients who start GLP-1 therapy plan for indefinite use, treating the drugs more like statins than like a course of antibiotics. The comparison is instructive: statins, too, lose their protective effect when discontinued.

The findings do not diminish the case for GLP-1 treatment. They complicate the exit strategy.

-- NORA WHITFIELD, New York